The AREDS2 results were published May 5, 2013 by the National Eye Institute in JAMA, the Journal of the American Medical Association. Based upon the results, Dr. Krawitz recommends that you change to VisiVite AREDS2 Plus+ Gold Formula when you are finished taking your current VisiVite supplement. The publication of these results can be found here:
http://jama.jamanetwork.com/article.aspx?articleid=1684847
STUDY HIGHLIGHTS:
- A modified AREDS Formula with both Lutein and Zeaxanthin, but without beta-carotene, was 18% more effective than AREDS1.
- Lutein and Zeaxanthin absorption was improved when beta-carotene was removed from the formula.
- Beta carotene was again proven to increase lung cancer in former smokers.
- No significant decrease in benefit was found with 25 mg Zinc versus 80 mg.
- Omega 3s were not found to be beneficial in Grade 3 and 4 macular degeneration patients.
- Vitamin E 400 IU risk: 1.6 (higher risk)
- Selenium 200 mcg risk: 0.8 (lower risk)
- Vitamin E plus Selenium risk: 0.4 (much lower risk)
- 50% more Lutein
- 138% more Zeaxanthin